EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT. A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at i
Kyverna Therapeutics advances Miv-cel for autoimmune diseases, but valuation, launch, and funding risks remain. Click here to read this analysis on KYTX.
Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.
Kyverna Therapeutics reports positive one-year clinical trial data for miv-cel in stiff person syndrome and myasthenia gravis.
Kyverna Therapeutics (NASDAQ:KYTX) reported one-year topline data from its KYSA-8 registrational trial of miv-cel, or mivocabtagene autoleucel, in stiff person syndrome (SPS), alongside longer-term follow-up results from the Phase 2 portion of its KYSA-6 trial in generalized myasthenia gravis (gMG). The company said the latest results provide follow-up on clinical outcomes and safety measures after patients received a single dose of the investigational cell therapy.
Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences: 2026 Wells Fargo Healthcare ConferenceFormat: Fireside chat and investor meetingsDate: Wednesday, September 9th, 2026Time: 4:30 p.m. ET Morgan Stanley 24th Annual Global Healthcare Conf
This is the newest page. Registered accounts read further back.